Major obstacles for personalized medicine according to pharma companies 2015
This statistic is based on a survey conducted during the 2nd quarter of 2015. It describes major obstacles for developing personalized medicines according to pharmaceutical companies in Asia, Europe, and in the United States. Most of respondents stated that the lack of a regulatory guidance would be the major obstacle for developing personalized medicines.